TABLE 4.

Adjusted PsO-Related Costs, IXE Versus SEC, IXE Versus ADA

Adjusted Cost Per Patient Per Month (Weighted)	Mean Cost Analysis				Median Cost Analysis
	IXE	SEC	Diff	P Value	IXE	SEC	Diff	P Value
Index drug costs, USD	5,613	4,626	987	<0.001	5,826	4,723	1,103	< 0.001
ICER discount rate	0.44	0.38			0.44	0.38
ICER-adjusted index drug costs (A), USD	3,143	2,868	275		3,263	2,928	334
PsO-related pharmacy costs, non-index drugs, USD	658	775	−117		11	22	−11
ICER average discount rate (across biologics)	0.30	0.31			0.30	0.31
ICER-adjusted PsO-related pharmacy costs, non-index drugs (B), USD	462	539	−77		8	16	−8
Unadjusted inpatient and outpatient costs (C), USD	32	36	−4		21	21	0
Total adjusted PsO-related costs (A + B + C), USD	3,637	3,443	195	0.132	3,546	3,311	235	0.002
Adjusted Cost Per Patient Per Month (Weighted)	Mean Cost Analysis				Median Cost Analysis
	IXE	ADA	Diff	P Value	IXE	ADA	Diff	P Value
Index drug costs, USD	5,328	3,588	1,740	< 0.001	5,555	3,716	$839	< 0.001
ICER discount rate	0.44	0.31			0.44	0.31
ICER-adjusted index drug costs (A), USD	2,984	2,476	508		3,111	2,564	$47
PsO-related pharmacy costs, non-index drugs, USD	427	1,134	−707		4	20	−16
ICER average discount rate (across biologics)	0.30	0.31			0.30	0.31
ICER-adjusted PsO-related pharmacy costs, non-index drugs (B), USD	300	778	−478		3	14	−11
Unadjusted inpatient and outpatient costs (C), USD	36	33	3		20	19	1
Total adjusted PsO-related costs (A + B + C), USD	3,320	3,287	33	0.907	3,332	3,047	285	0.002

ADA = adalimumab; Diff = difference; ICER = Institute for Clinical and Economic Review; IXE = ixekizumab; PsO = psoriasis; SEC = secukinumab.